SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

CleanSpark, Inc. is a bitcoin mining technology company, which engages in the management of data centers. Its operations include College Park, Norcross, Washington, Sandersville, Dalton, and Massena. The company was founded by S. Matthew Schultz and Bryan Huber on October 15, 1987 and is headquartered in Henderson, NV.

Cleanspark Inc

Cleanspark is trending amid discussions around its upcoming earnings report and pivot towards AI and high-performance computing, with some speculating on a potential 'Saudi deal.' The community is weighing the impact of a recent convertible note offering and share buyback, alongside broader market trends affecting Bitcoin miners. Some traders are expressing concerns about debt and dilution, while others see the dip as a buying opportunity based on the company's long-term prospects.

Dell Technologies, Inc. is a technology company, providing customers with a broad and innovative solution portfolio to help customers modernize their information technology (IT) infrastructure, address workforce transformation, and offer critical solutions that keep people and organizations connected. It operates through the following segments: Infrastructure Solutions Group (ISG) and Client Solutions Group (CSG). The ISG segment includes servers, networking, and storage, as well as services and third-party software and peripherals that are closely tied to the sale of ISG hardware. The CSG segment includes designs for commercial and consumer customers of desktops, thin client products, and notebooks. The company was founded by Michael Saul Dell in 1984 and is headquartered in Round Rock, TX.

Dell Technologies Inc - Ordinary Shares - Class C

Dell Technologies Inc

Dell is trending as discussions revolve around its potential as an AI beneficiary, underscored by strong server demand and a low P/E ratio, with community members pointing to a potentially significant surge following earnings. Bullish sentiment is fueled by positive AI outlooks with counter arguments focused on margin concerns. Some traders are closely watching options activity and analyst ratings in anticipation of the earnings report.

Kohl's Corp. engages in the operation of family-oriented department stores. Its business line includes apparel, footwear, and accessories for women, men, and children, home products, beauty products, and accessories. The stores generally carry a consistent merchandise assortment with some differences attributable to regional preferences. The company was founded in 1962 and is headquartered in Menomonee Falls, WI.

Kohl`s Corp.

Kohl's Corp

Kohl's stock is trending due to a surprise Q3 profit and raised full-year EPS guidance, triggering meme-stock style trading and a short squeeze. The community is actively discussing the potential for a continued squeeze and the company's improving financial outlook. Sentiment is bullish, with some anticipating further gains due to high short interest and renewed retail interest.

Kazia Therapeutics Ltd. is an oncology-focused biotechnology company, which engages in the business of pharmaceutical drug development. It focuses on its Paxalisib program, which is designed to treat brain cancer. The company was founded by Graham Edmund Kelly in March 1994 and is headquartered in Sydney, Australia.

Kazia Therapeutics Limited - ADR

Kazia Therapeutics

KZIA is trending due to positive clinical data showing a complete response in a breast cancer patient, sparking optimism and heavy trading volume. Community members are discussing the potential for a short squeeze and speculating on future price targets. The focus remains on the company's cancer treatment and upcoming presentations.

Abercrombie & Fitch Co. engages in the retail of apparel, personal care products, and accessories. The firm operates through following geographical segments: Americas, EMEA and APAC. The Americas segment includes operations in North America and South America. The EMEA segment includes operations in Europe, the Middle East and Africa. The APAC segment includes operations in the Asia-Pacific region, including Asia and Oceania. The company was founded by David Abercrombie in 1892 and is headquartered in New Albany, OH.

Abercrombie & Fitch Co. - Ordinary Shares - Class A

Abercrombie & Fitch Co.

Abercrombie & Fitch is trending following positive Q3 results that exceeded expectations and led to an increased fiscal 2025 outlook. Community members are weighing whether to buy more shares, while some are eyeing potential shorting opportunities based on past patterns after earnings. The stock's low P/E ratio is also a point of discussion, with some bulls anticipating a continued climb.

Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company, which focuses on the discovery, acquisition, and development of small molecules and biologics to treat and prevent human disease and alleviate suffering. Its portfolio includes TNX-102 SL, TNX-601, TNX-801, and TNX-1800. The company was founded by Seth Lederman and Donald W. Landry on November 16, 2007 and is headquartered in Chatham, NJ.

Tonix Pharmaceuticals Holding Corp

TNXP is trending as the community debates its future following the commercial launch of Tonmya and a recent announcement regarding share buybacks. Discussions range from the potential for a short squeeze given the low float, to skepticism fueled by the company's history of dilution and reverse stock splits. Investors are closely watching for upcoming sales data to gauge the drug's market performance.

Zscaler, Inc. engages in the provision of a cloud-based internet security platform. It offers Zero Trust Exchange, Zscaler Client Connector, Zscaler Internet Access, Zscaler Private Access, Zscaler B2B, Zscaler Cloud Protection, and Zscaler Digital Experience. The company was founded by Jagtar Singh Chaudhry and K. Kailash in September 2007 and is headquartered in San Jose, CA.

Zscaler Inc

Zscaler is trending as the community discusses recent performance and future growth prospects following its earnings report, with particular attention to guidance and valuation. Community members are weighing whether recent price movements present a buying opportunity or indicate deeper concerns about the company's outlook. Discussions also involve the broader cybersecurity sector and Zscaler's competitive positioning.

Strategy, Inc. engages in the provision of enterprise analytics and mobility software. The firm designs, develops, markets, and sells software platforms through licensing arrangements and cloud-based subscriptions and related services. Its product packages include Hyper. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Vienna, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

MSTR is trending amid discussions of a potential short squeeze, with some traders scrutinizing its correlation with Bitcoin's price movements. Concerns around JP Morgan's influence and MSTR's market cap relative to its Bitcoin holdings are also circulating. The community is actively debating if MSTR will decouple from BTC or if a significant rally is imminent.

Paramount Skydance Corp. is a next-generation global media and entertainment company that engages in providing content creation and distribution services. It operates through the following business segments: Studios, Direct-to-Consumer, and TV Media. Its portfolio unites brands including Paramount Pictures, Paramount Television, CBS, CBS News, Nickelodeon, MTV, BET, Comedy Central, Showtime, Paramount Plus, Pluto TV, and Skydance’s Animation, Film, Television, Interactive/Games, and Sports divisions. The company was founded on June 3, 2024 and is headquartered in New York, NY.

Paramount Skydance Corp. - Ordinary Shares - Class B

Paramount Skydance Corp. (PSKY) is trending amid speculation of a potential bidding war with Comcast and Netflix for Warner Bros. Discovery (WBD). Community discussions revolve around whether PSKY will prevail, with many bullish investors anticipating significant upside if the acquisition occurs, while others express concerns over potential debt and regulatory hurdles. Recent news includes earnings reports and a strategy update from CEO David Ellison which the community is closely analyzing.

Aurinia Pharmaceuticals, Inc. is a clinical stage bio-pharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Edmonton, Canada.

Aurinia Pharmaceuticals Inc

AUPH is trending on high volume and positive community sentiment following encouraging news, possibly tied to earnings or pipeline developments. Traders are actively discussing a potential breakout and are closely watching for further catalysts. The community speculates on the potential for a buyout, driven by the company's strategic position and recent financial performance.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$ONCSQ Phase 2 trial w/est Nov completion date NCT04526730: https://www.clinicaltrials.gov/study/NCT04526730 Trial Tracker: https://www.fdatracker.com/trial-tracker/

Clinicaltrials

CTG Labs - NCBI

Sign up or log in to access Trial Tracker! This limited demo only displays Phase 3 trials with primary completion dates within the last 3 months for companies with a market cap less than $1B. FDA Tracker Membership unlocks all of the selection criteria to help you screen the full range of clinical trial catalysts.